Rheumatoid Arthritis Drug Discoveries: what the future holds

Date: March 22, 2008
Pages: 250
Price:
US$ 1,740.00
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: RB322CDC385EN
Leaflet:

Download PDF Leaflet

Rheumatoid Arthritis Drug Discoveries: what the future holds
With significant unmet clinical need and the progressive introduction of higher value and effective biopharmaceuticals, the rheumatoid arthritis market is expected to more than double in value to US$27 billion by 2015. This new management report provides a complete examination of the RA market and its prospects in the medium term. Prevalence and incidence – where in the world?

Rheumatoid arthritis is the most common chronic inflammatory joint disease. The incidence of RA among white populations is approximately 3 people per 10,000 or 0.03 per cent per annum worldwide, although this can vary markedly between different regions. RA is rare in rural and less developed parts of the world; indeed, one large study in Nigeria failed to find a single case of RA. It is also known to be rare in China and Indonesia, and the incidence is very low in Japan, suggesting urbanised and westernised lifestyles may have a key role in the onset of the disease.

RA is relatively uncommon in patients aged less than 15 years, with incidence increasing up to the age of 70 years before tailing off. The commonest age of onset is between 40 and 50 years of age. Overall, the prevalence in North America and the European Union is expected to increase until at least 2010, due to the aging population. At the same time, prevalence in rural countries is expected to continue to increase.

A rising market

We estimate the global rheumatoid arthritis market was worth approximately US$11.6 billion in 2007, accounting for 1.7 per cent of global pharmaceutical sales (which were US$691.2 billion in 2007). Global sales include the non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, traditional disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate, (MTX), and the biologic therapies. The biologics account for the greatest proportion of sales, although the majority of patients are still treated with the traditional DMARDs.

By 2015, we expect the global RA market to generate sales of around US$27 billion due to the growth in sales of existing and new biologic therapies, which will remain as the main growth drivers. The new oral therapies will begin to make a further impact on market growth from 2011. The uptake of these more effective newer agents will lead to a decline in sales of established treatments to 2015.

Price pressure and safety: blocks to growth?

Against these possibilities for future market growth, there looms the spectre of the financial strain placed on healthcare systems by the prescription of highly-priced biologics, which may limit their use. In the treatment of RA, the cost of the new biologics is considerably higher than the cost of the traditional treatments. In addition, unexpected safety issues may impact market growth of the RA market as a whole. For instance, the withdrawal of Merck & Co's Vioxx and Pfizer's Bextra has seen a slowdown in the uptake of Cox-2 inhibitors in the treatment of the signs and symptoms of RA.

Questions answered
  • Who will be the leading players in the RA market in 2015 and what products and approaches will be influential?
  • What advantages will the new generation of biopharmaceuticals have over existing treatments?
  • How extensive is Pfizer’s development portfolio in RA?
  • How important will combination therapy be in the RA sector?
  • Enbrel, Remicade and Humira – who will win the battle for sales, and why?
  • Evaluation and forecasts for leading therapies and prospects include...


Currently available
Celebrex
Remicade
Humira
Enbrel
Kineret
Rituxan/MabThera
Orencia

Phase III/Filed
Golimumab
Actemra
Cimzia
Ofatumumab
Ocrelizumab

Phase II
CP-690550
CP-195543
TRU-015
SCIO-469
Baminercept
Denosumab
AMG 108
Atacicept
Tamatinib
LymphoStat-B
RhuDex
CF101
SC12267
INTRODUCTION

WHAT IS RHEUMATOID ARTHRITIS?


Pathogenesis Of Rheumatoid Arthritis
Classification Of Rheumatoid Arthritis
Assessment Of Disease Activity And Response To Treatment

CURRENT TREATMENT OPTIONS

Diagnosis of Rheumatoid Arthritis
Pharmacological Therapy
Treatment Strategies

PATIENT STATISTICS

Incidence and Prevalence
The Future

THE RHEUMATOID ARTHRITIS MARKET

Players And Products
Players And Products In 2007
Players And Products In 2015
Drug Growth Drivers and Dampeners

ANALYSIS OF CURRENT LEADING PRODUCTS

Non-Steroidal Anti-Inflammatory Drugs
  Celebrex
  Arcoxia
  Mobic
Glucocorticoids
Traditional Disease-Modifying Anti-Rheumatic Drugs
Biological Agents
TNF Inhibitors
  Remicade
  Humira
  Enbrel
Interleukin-1 Receptor Inhibitor
  Kineret
B-Cell Targeted Therapy
  Rituxan/MabThera
T-Cell Co-Stimulation Modulator
  Orencia

RESEARCH AND DEVELOPMENT OF RHEUMATOID ARTHRITIS DRUGS

Late-Phase Projects
  TNF Inhibitors
    Cimzia
    Golimumab
  Interleukin-6 Receptor Inhibitor
    Actemra
  Interleukin-1 Receptor Inhibitor
    Canakinumab
  B-Cell Targeted Therapy
    Ocrelizumab
    Ofatumumab
  Non-Steroidal Anti-Inflammatory Drugs
    Iguratimod
    PN-400
  Glucocorticoid
    Lodotra
PHASE II PROJECTS
Oral Therapies
  Adenosine Receptor Antagonist
    CF101
  Cathepsin-S Inhibitor
    RWJ-445380
  Chemokine Receptor Antagonists
    Selzentry
  DHODH Inhibitor
    SC12267
  Interleukin Inhibitors
    Apilimod
  Kinase Inhibitors
    681323
    856553
    BMS-582949
    CP-195543
    CP-690550
    INCB18424
    PH-797804
    SCIO-469
    Tamatinib
    VX-702
  T-Cell Co-Stimulation Modulator
    RhuDex
  Other Oral Therapies
    274150
    CH-1504
    CRx-102
    K-832
    PMI-001
    R7277
Injectable Therapies
  B-Cell Targeted Therapy
    Atacicept
    LymphoStat-B
    TRU-015
  Interleukin Inhibitors
    AMG 108
  Lymphotoxin Beta and LIGHT Pathway Inhibitor
    Baminercept
  RANK Ligand Inhibitor
    Denosumab
  TNF Inhibitor
    tgAAC94
  Other Injectable Therapies
    MM-093
PHASE I PROJECTS
Kinase Inhibitors
  ARRY-438162
  ARRY-797
  MLN0415
  Anti-TNF
    ART621
  Others
    PRTX-100
    VAP-1
APPENDIX 1: COMPETITOR RATIO ANALYSIS

APPENDIX 2: COMPANY PROFILES


4SC
Abbott
Amgen
Arana Therapeutics
AstraZeneca
Biogen Idec
Bristol-Myers Squibb
Can-Fite Biopharma
Chelsea Therapeutics
Chugai
CombinatoRx
Dainippon Sumitomo Pharma
Eisai
Eli Lilly
Genmab
GlaxoSmithKline
Human Genome Sciences
Johnson & Johnson
Kowa Pharmaceutical
Medarex
Medigene
Merck KGaA
Merrimack Pharmaceuticals
Millennium Pharmaceuticals
Mitsubishi Tanabe Pharma
Novartis
Phytomedics
Pozen
Pfizer
Rigel Pharmaceuticals
Roche
sanofi-aventis
Schering-Plough
Synta Pharmaceuticals
Takeda
Targeted Genetics
Toyama Chemical
Trubion
Wyeth
Vertex Pharmaceuticals

APPENDIX 3: GLOSSARY

APPENDIX 4: SOURCES

APPENDIX 5: PRODUCT INDEX

INDEX OF TABLES


Traditional DMARDs used in the treatment of RA
ACR responses
Products In Development For The Treatment Of Rheumatoid Arthritis
Competitor Ratio Analysis Scores
Six- and 12-month ACR responses for RAPID 1
Six and 12 month mean mTSS changes from baseline for RAPID 1
Competitor Ratio Analysis Scores
Competitor Ratio Analysis Summary

INDEX OF CHARTS

Synovitis And Joint Destruction In Rheumatoid Arthritis
Bone Erosion In Untreated Rheumatoid Arthritis
Current Views On The Pathogenesis Of Rheumatoid Arthritis
Guidelines For The Management Of Rheumatoid Arthritis
Global Rheumatoid Arthritis Drug Sales (2007E)
Rheumatoid Arthritis Market (2007E-2015E)
Global Market Share of Major Biologic RA Products (2007E)
Global Market Share Of RA Biologics And Oral Therapies By Sales (2015E)
Celebrex RA Sales (2008E-2015E)
Remicade RA Sales (2008E-2015E)
Humira RA Sales (2008E-2015E)
Enbrel RA Sales (2008E-2015E)
Kineret RA Sales (2008E-2015E)
Rituxan/MabThera RA Sales (2008E-2015E)
Orencia RA Sales (2008E-2015E)
Launch Of Biologics In Late-Phase Development To Treat Rheumatoid Arthritis
Cimzia RA Sales (2008E-2015E)
Golimumab RA Sales (2009E-2015E)
The Role Of IL-6 In Inflammation
Actemra RA Sales (2008E-2015E)
Ocrelizumab RA sales (2011E-2015E)
Ofatumumab RA Sales (2010E-2015E)
CF101 RA Sales (2012E-2015E)
SC12267 RA Sales (2011E-2015E)
CP-195543 RA Sales (2012E-2015E)
CP-690550 RA Sales (2011E-2015E)
Scio-469 RA Sales (2012E-2015E)
R788 RA Sales (2011E-2015E)
RhuDex RA Sales (2012E-2015E)
Atacicept RA Sales (2011E-2015E)
LymphoStat-B RA sales (2011E-2015E)
TRU-015 RA Sales (2011E-2015E)
AMG 108 RA Sales (2011E-2015E)
Baminercept RA Sales (2010E-2015E)
Denosumab RA Sales (2009E-2015E)
Skip to top


Breast Cancer Drug Discoveries: What the Future Holds US$ 3,145.00 Aug, 2011 · 382 pages
Blood Cancer Drug Discoveries: what the future holds US$ 2,265.00 Apr, 2008 · 245 pages
Obesity Drug Discoveries: what the future holds US$ 1,740.00 Aug, 2007 · 116 pages
Prostate Cancer Drug Discoveries: What the Future Holds US$ 2,265.00 Nov, 2009 · 160 pages

Ask Your Question

Rheumatoid Arthritis Drug Discoveries: what the future holds
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: